
## Si-Cong

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7580237/publications.pdf Version: 2024-02-01



SI-CONC

#	Article	IF	CITATIONS
1	Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice. BMC Medicine, 2022, 20, 120.	5.5	5
2	Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. OncoImmunology, 2021, 10, 1909296.	4.6	13
3	De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma. Frontiers in Oncology, 2021, 11, 666145.	2.8	2
4	Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy. Cancer Management and Research, 2021, Volume 13, 4541-4551.	1.9	2
5	Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage. BMC Medicine, 2021, 19, 322.	5.5	О
6	Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions. Frontiers in Oncology, 2021, 11, 772604.	2.8	1
7	Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer. Theranostics, 2020, 10, 11080-11091.	10.0	111
8	Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud. , 2020, 8, e000381.		35